GlassScriptPhysician profile
Stephanie Prieto
NPI 1386344182
$6,982.81
in general payments reported to CMS, 2019-2025
24 companies · $2,746 in 2025
The $2,746 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,987 · 2024: $2,249 · 2025: $2,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,982.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,902.91 | 2023-2025 | Briviact, Fintepla, Nayzilam |
| Jazz Pharmaceuticals INC. | $1,139.13 | 2023-2025 | Epidiolex |
| Abbvie INC. | $941.02 | 2023-2024 | |
| Neurelis, INC. | $631.21 | 2023-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $290.45 | 2023-2025 | Fycompa |
| Livanova USA, INC. | $276.16 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $238.32 | 2023-2024 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $201.03 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $192.41 | 2024 | Rexulti |
| Sk Life Science, INC. | $175.66 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $168.34 | 2025 | Koselugo |
| Ge Healthcare | $148.56 | 2024 | |
| Eisai INC. | $147.91 | 2023-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $135.78 | 2025 | Rejoyn |
| Corium, LLC | $93.22 | 2025 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $50.67 | 2025 | Ztalmy |
| Biogen, INC. | $48.36 | 2025 | Spinraza, Skyclarys |
| Upsher-Smith Laboratories LLC | $45.87 | 2025 | |
| Azurity Pharmaceuticals, INC. | $42.73 | 2025 | Zonisade |
| Ptc Therapeutics, INC. | $31.60 | 2025 | |
| Genentech USA, INC. | $24.90 | 2025 | Evrysdi |
| Aucta Pharmaceuticals, INC. | $22.82 | 2025 | Motpoly Xr |
| Itf Therapeutics LLC | $20.82 | 2025 | |
| Acadia Pharmaceuticals INC | $12.93 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Prieto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.